Our Team

Mr. Will Wonhyung Park

Founder & Chief Executive Officer
Mr. Park has been leading the executive management and commercial affairs of TSG since its establishment in 2016. He has extensive experience in the finance industry, building and leading several business groups across Asia on behalf of global investment banks. Prior to TSG, he was Managing Director and Head of the Strategic Investment Group at Deutsche Bank Group in Japan. Before joining Deutsche Bank, he held a number of positions with Morgan Stanley Properties based in Korea.

Dr. Patricia Fast, M.D., Ph.D.

Chief Technology Officer
Dr. Fast has been working to solve global concerns of viral infectious diseases for over 30 years. She has served multiple leading roles with international governmental organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) where she oversaw early HIV vaccine trials.

At International AIDS Vaccine Initiative (IAVI), as Chief Medical Officer, she oversaw 28 clinical trials; including HIV, Yellow Fever, and Hepatitis B vaccines. In addition, she held industry positions at Aviron (now Medimmune/AstraZeneca), where she was responsible for studies of live attenuated intranasal Influenza vaccine (now licensed as FluMist) and live attenuated Cytomegalovirus vaccine. She was also seconded to the World Health Organization in 2014-15 to assist with Ebola vaccine trials in response to the outbreak (ERVEBO is now licensed). Currently, she is leading the clinical studies of Lassa Fever vaccine and plays a key advisory role for products that are designed to prevent Marburg hemorrhagic fever and HIV (monoclonal antibodies and vaccine).

Dr. Fast currently holds an adjunct clinical associate professorship at Stanford University School of Medicine and serves as senior technical advisor for IAVI, for epidemiology and product clinical development. She is an Academic Editor for PLOS One, has served on a number of Data and Safety Monitoring Boards for drug and vaccine projects and has published over 100 papers in peer reviewed journals.

Dr. Myungchol Kang, Ph.D.

Chief Development Officer
Dr. Kang has extensive scientific management experience in drug discovery research, pharmacology, process R&D, analytical science, regulatory affairs, and chemical manufacturing operations within the pharmaceutical industry. He held positions at various organizations including Glaxo Inc, Trimeris Inc and Kainos Medicine.

At Glaxo, he was head of process research, development chemistry, commercial development projects and pilot plant operations in the chemical development department. He successfully managed projects including antivirals, amylin antagonist and anticancer agents, and set up two laboratories for large-scale solid-phase peptide synthesis. At Trimeris, he was responsible for all aspects of technical research and development including discovery chemistry, process chemistry, pharmaceutical science, primary and secondary manufacturing, and CMC regulatory. He spearheaded the development of an innovative manufacturing process to make unprecedented amounts of the complex peptide, Fuzeon(T-20, 36mer peptide) which is an AIDS drug. He was also a member of the joint steering committee of the Fuzeon project between Roche and Trimeris. Dr. Kang was a co-founder and co-chief executive of Kainos Medicine, and has experience in the successful initial public offering of Trimeris in NASDAQ.

Dr. Emily Wood Carrow, Ph.D.

Director, Research & Development
Dr. Carrow has 30+ years of experience in the field of Infectious Diseases. She has held scientific managerial positions at various organizations including the U.S. Food and Drug Administration (FDA), DuPont Pharmaceuticals, International AIDS Vaccine Initiative (IAVI) and Advanced BioAdjuvants.

At FDA, she served as chairperson / member of committees to review IND, IDE, PLA/ELA, and PMA applications for products designed to detect evidence of retrovirus infection in blood and other body fluids. Scientific review included evaluation of product manufacturing and quality control procedures, preclinical and clinical data, intended use and labeling. She oversaw the regulatory approval of the first diagnostic test for HIV antibodies in saliva, including the first Western blot confirmatory tests for HIV antibodies. She also helped develop policies and guidelines.

Dr. Carrow also has practical experience in scientific research, process development, regulatory affairs, program management, intellectual property review and business development in non-profit and business settings. At IAVI, she managed the Neutralizing Antibody Consortium, which helped to design and develop an effective HIV vaccine and she was also involved in the implementation of new technologies. Most recently at Advanced BioAdjuvants, Dr. Carrow was instrumental to the successful development of a novel vaccine adjuvant from the discovery stage to the clinic. She implemented a clinical supply agreement to provide the adjuvant for a Phase 1 human clinical trial of a vaccine under a US FDA IND and completed technology transfer of the adjuvant to the U.S. National Institutes of Health for use in clinical trials of various vaccines.

Ms. Yvonne Eng

Manager, Business Operations and Information Technology
Ms. Eng is responsible for the overall operational affairs of TSG since 2017. She has 20 years of experience as an analyst and project manager in the IT Healthcare industry, focusing on innovative healthcare solutions, supporting clinicians in research and education and vendor management. She had been involved in tender processes from the Request for Proposal (RFP) stage to tender award.

Prof. Cecil Czerkinsky, DMD, Dr Med Sci, Ph.D.

Chief Scientific Advisor
Dr. Czerkinsky has extensive experience in immunology and infectious diseases. He also serves as Emeritus Research Director for the French National Institutes of Health and Medical Research (INSERM) at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC).

He had previously served as Professor at the University of Göteborg Medical Faculty (Sweden), Deputy Director General and Head of R&D at the International Vaccine Institute (IVI), headquartered in Seoul, and prior to that as Director of the Mucosal Immunology & Vaccinology division at INSERM in Nice.

He has published over 200 research and review articles with a main focus on vaccine science. He is the inventor of several proprietary technologies pertaining to mucosal vaccines, immunotherapy and immunodiagnostics that have been licensed to major pharma corporations. He has co-founded several biotechnology companies, including one which became public. He is also the inventor of the ELISpot assay, a technique used worldwide for measuring human immune responses.

Dr. Czerkinsky has held various academic appointments including tenured or adjunct faculty professorships in universities in the US, Sweden and Seoul. He had also served as adviser for various national, international and supranational (WHO, ESSAC) agencies and foundations.

Dr. Nancy C. Motola, Ph.D., RAC,

Regulatory Affairs Advisor
Dr. Motola Dr. Motola has over 30 years of experience in the Pharmaceutical Industry, encompassing both small molecules and biologics, in many therapeutic areas; in regulatory affairs and quality assurance, as well as chemical development/ manufacturing.

She has held many leadership roles in pharmaceutical companies. In these roles, she was part of the management team, built and managed the product compliance organization, and was responsible for the approvals of drug products such as Soliris, a monoclonal antibody for a rare hematological condition and other rare diseases, and Durlaza, a controlled release aspirin product for secondary prevention of acute cardiac events. In Regulatory Affairs, Dr. Motola had achieved approvals of several marketed products at Bayer Corp., Abbott Laboratories, and E.R. Squibb & Sons, Inc. where she also started her career as a process chemist.

She is also a member of various Scientific Advisory Boards and a founder & past chair of the Regulatory Sciences Section of the American Association of Pharmaceutical Scientists (AAPS), and a frequent contributor to industry and educational programs.

Dr. Sven Enterlein, Ph.D.

Consulting Scientist
Dr. Enterlein has over 10 years of experience in antiviral drug development and coordinating preclinical studies. Previously, he was the Associate Director of Antiviral Services at Integrated BioTherapeutics and Program Director at TSG Therapeutics.

Mr. Jim Ackland

Consulting Specialist for Development
Mr. Ackland has extensive experience in the manufacture, quality control, development and international regulatory requirements for pharmaceutical products. This includes senior management positions in the manufacture, quality assurance and research and development at CSL Limited, Australia. He was formerly Head of Regulatory Affairs for Vaccine Products at CSL Limited (Australia) and subsequently, he was Vice President/ Senior Consultant for the Biologics Consulting Group (USA), an internationally recognized pharmaceutical regulatory consulting company. Since 2005, he has been providing regulatory and product development advice and assistance to pharmaceutical and biotech companies.

Mr. Ackland has been involved in many pharmaceutical development projects as the lead regulatory advisor/negotiator and preclinical safety expert. He has filed numerous successful clinical trial applications in the US, Europe and in Australia.

Mr. Anthony Flynn

Senior Advisor
Mr. Flynn has an extensive background in resource mobilization in support of global health initiatives and institutions.  He has served as Director of Development at the International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b); as Deputy Director General of the International Vaccine Institute in Seoul, Korea; and as Head of Development at the International AIDS Society in Geneva, Switzerland.  He also supported the resource mobilization programs of a leading public-private global health partnership, the International AIDS Vaccine Initiative (IAVI) where he served as Manager of Development at IAVI’s European headquarters.  Previously, he worked for a number of educational, scientific and cultural organizations in the United States, including the New York Public Library, the American Museum of Natural History and Lincoln Center for the Performing Arts.

Mr. Kisub Lee

Senior Advisor
Mr. Lee is the CEO and co-founder of Kainos Medicine which is an established biotech company that develops numerous drugs for cancer, diabetes, neurodegenerative diseases, and others. Mr. Lee successfully managed the company from startup to public company by IPO in 2020. Mr. Lee is also the Chairman of the Board of Mirakle51, a unique service platform for early-to-mid stage ventures. Prior to Kainos Medicine, Mr. Lee co-founded Silicon Image, Inc. in Silicon Valley, which developed semiconductors for communications applications. He had a successful IPO for Silicon Image in 1999. He was also the founding CEO of GCT Semiconductor, a fabless semiconductor company that developed innovative integrated circuit solutions for the wireless communications industry.